Regulatory Amgen’s BiTE for lung cancer backed for EU approval PharmaphorumAmgen's fast-growing bispecific T-cell engager Imdylltra should be cleared as a second-line therapy for small cell lung cancer, said the CHMP.RegulatoryOncologyRead full story pharminent March 30, 2026 (Last updated: March 30, 2026) Pharmaphorum Amgen’s fast-growing bispecific T-cell engager Imdylltra should be cleared as a second-line therapy for small cell lung cancer, said the CHMP. RegulatoryOncologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Trustworthy AI in clinical oversightNext: The Top Pharmacy Benefit Managers of 2025: Market Share and Key Industry Developments Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
